Accueil   Agenda - News   Toutes les news Successful Industrial GMP Manufacturing of RIBOXXIM, a Novel and Highly Potent Toll-like 3 Ligand for Immunotherapy of Cancer

Successful Industrial GMP Manufacturing of RIBOXXIM, a Novel and Highly Potent Toll-like 3 Ligand for Immunotherapy of Cancer

Radebeul, Germany & Lyon, France, September 15, 2017 -- RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and ACCINOV, a pharmaceutical establishment for experimental drug products, today announced the successful industrial GMP manufacturing, including packaging and quality control of RIBOXXIM®, a novel and highly potent Toll-like Receptor 3 (TLR3)-ligand.





Manufacturing has been performed with the patented process TENPORA® of RIBOXX in full compliance with the EU GMP requirements, and with the GMP specifications of the experimental drug.


RIBOXXIM® is a proprietary drug substance of RIBOXX PHARMACEUTICALS. It activates the innate immune system to eliminate cancer cells as a validated approach in immuno-oncology with the historical TLR3 ligand poly(I:C) and its derivatives.


RIBOXXIM® has been validated in multiple pre-clinical studies for immunotherapy of cancer. It displays unique physico-chemical and biological properties, as well as optimal biodisponibility with increased stability to degradation in body fluids such as human plasma. RIBOXXIM® is stable as a drug product in liquid form for several months.


Prof. Dr. Jacques Rohayem, CEO and CSO of RIBOXX PHARMACEUTICALS declared: "We are proud to have reached this important milestone in the development of TLR3 ligands, with a unique, highly potent and stable drug product as a better alternative to poly(I:C) and its derivatives. RIBOXXIM® is available for pharmaceuticals companies or universities developing clinical applications in immuno-oncology and therapeutic vaccines."


André Dupont, President of ACCINOV declared: “We are proud to be the manufacturer of this innovative experimental drug. This achievement demonstrates the high flexibility of the ACCINOV model.”

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à Plus de détails sont disponibles en cliquant ici J'accepte